

The best African plant-derived antibacterial products for clinical perspectives: The state-of-the-art

Victor Kuete^{1*}

Abstract

Background: The global burden of bacterial infections remains a serious health concern. In the present review, we have summarized the best botanicals and phytochemicals from the flora of Africa that deserve clinical studies to develop novel antibacterial drugs to combat enterobacteria, *Pseudomonas aeruginosa*, Gram-positive bacteria, and mycobacteria.

Methods: Data were retrieved from scientific databases such as PubMed, Scopus, ScienceDirect, Google Scholar, and Web of Science using the keywords "African country and plant and antibacterial" and plants or phytochemicals with outstanding antibacterial activities following established cutoff point standards were selected.

Results: The identified botanicals were from *Acacia polyacantha*, *Alchornea floribunda*, *Artemisia abyssinica*, *Beilschmiedia acuta*, *Eriosema glomeratum*, *Harungana madagascariensis*, *Macaranga capensis*, *Macaranga conglomerata*, *Macaranga kilimandscharica*, *Mangifera indica*, *Piper nigrum*, *Piptadeniastrum africanum*, and *Uapaca togoensis*. The phytochemicals identified included 2-(4-hydroxyphenyl)-ethyltriacontanoate (1), 1,3,5,6-tetrahydroxyxanthone (2), 1,3,5,7-tetrahydroxyxanthone (3), 8,8-bis-(dihydroconiferyl) diferulate (4), 2-hydroxy-3-methoxy-9,10-dioxo-9,10-dihydroanthracene-1-carbaldehyde (5), allanxanthone D (6), *angusticornin* B (7), bartericin A (8), diospyrone (9), dorsmanin C (10), gancaonin Q (11), isobavachalcone (12), isoliquiritigenin (13), laburnetin (14), O¹-demethyl-3',4'-deoxy-psorospermi-3',4' diol (15), plumbagin (16), and vismiaquinone (17).

Conclusion: These plant-derived products deserve clinical investigations to develop novel antibacterial agents to combat bacterial infections.

Keywords: Africa; antibacterial; botanicals; phytochemicals

*Correspondence: Phone: +237 677355927; E-mail: kuetevictor@yahoo.fr; ORCID : <http://orcid.org/0000-0002-1070-1236> (Victor Kuete).

¹Department of Biochemistry, Faculty of Science, University of Dschang, Dschang, Cameroon.

Citation on this article: Kuete V. The best African plant-derived antibacterial products for clinical perspectives: The state-of-the-art. *Investigational Medicinal Chemistry and Pharmacology* (2024) 7(2):94; Doi: <https://dx.doi.org/10.31183/imcp.2024.00094>



Background

The global burden of bacterial infections remains a serious health concern. This situation is more complicated as bacteria continually develop various resistance mechanisms to existing and newly discovered antibiotics [1-4]. It was reported that up to 700,000 people worldwide die yearly due to drug resistant infections [5]. It was also projected that by 2050, the number of deaths due to microbial infections will reach 4.73 million in Asia, 4.15 million in Africa, 0.39 million in Europe, 0.392 million in Latin America, 0.317 million in North America, and 0.022 million in Oceania [6]. In-depth search of new antibacterial drugs should remain a priority for scientists to limit as much as possible the damage caused by infectious diseases, including those caused by resistant pathogens. The role of medicinal plants as a good source of drugs to tackle human ailments including the various type of diseases with resistant phenotypes has been largely documented [7-35]. Increasingly, new strategies for discovering new bioactive substances from natural sources include the use of multidrug-resistant models. This has been particularly successful in the search for novel anticancer, antibacterial, and antifungal drugs, as well as new antiparasitic and antiviral drugs in the last two decades. Numerous research teams such as those of Professors Thomas Efferth of the University of Mainz in Germany and Victor Kuete of the University of Dschang in Cameroon have invested heavily in recent years in multidrug-resistant models of cancer cells and bacteria overexpressing efflux pumps [36-43]. The role of African plants and their constituents as potential sources of antibacterial agents have deeply been demonstrated [44-46]. The ability of many of the antibacterial plants from the flora of Africa and their constituents to prevent the development of multidrug-resistant (MDR) bacteria has been reported [47-51]. The research for novel plant-derived antibacterial agents has been particularly fruitful in some African countries such as Egypt, South Africa, Nigeria, Tunisia, and Cameroon. In the present review, the state-of-the-art antibacterial drug discovery from the resource of Africa will be highlighted.

Methods

Data were retrieved from scientific databases such as PubMed, Scopus, ScienceDirect, Google Scholar, and Web of Science using the keywords "African country and plant and antibacterial" and plants or phytochemicals with outstanding antibacterial activities following cutoff point standards earlier established for enterobacteria, *Pseudomonas aeruginosa*, Gram-positive bacteria, and mycobacteria [52-55].

Results and discussion

History of the antimicrobial drug research in Africa

When using the combination of keywords (country + plant + antibacterial) in the PubMed database, though not accurate, an idea of the history of medicinal plant research in Africa about bacterial infections has been determined (Table 1). The first paper on the topic was published on the Egyptian plant *Nigella sativa* L. Ranunculaceae) by Topozada and co-workers in 1965 [56]. In general, in most African countries, this research began in the 70s

in Nigeria, Kenya, and Ghana, 80s in Sudan, 90s in South Africa, Cameroon, Morocco, Ethiopia, and Algeria, and even in 2000 in Tunisia. By April 2024, the number of scientific publications in the PubMed database related to the above combination of keywords showed a huge gap between African countries, with countries such as Egypt, South Africa, Nigeria, Tunisia, and Cameroon appearing in the top 5 with more than 300 published papers. Other African countries with more than 100 scientific publications included Morocco, Ethiopia, and Algeria, meanwhile less than 100 papers were found for Kenya, Ghana, and Sudan (Table 1).

The antibacterial cutoff points

In 2008, the first threshold values were suggested by Fabry et al. as minimal inhibitory concentration (MIC) values below 8 mg/mL for botanicals with noteworthy antimicrobials [57]. Since then, things have evolved and plant extracts with MIC values above 1000 µg/mL are now considered not active. Later on, Simoes et al. suggested the MIC in the range of 100 to 1000 µg/mL for phytochemicals as antimicrobial agents [58]. Also, Jimenez-Arellanes suggested MICs between 100-200 µg/mL as interesting for crude extracts [59]. In 2010, Kuete [60] suggested ranking the antibacterial effects of plant-derived products as follows: significant (MIC < 100 µg/mL), moderate (100 < MIC ≤ 625 µg/mL) or weak (MIC > 625 µg/mL) for crude extracts and also that significant (MIC < 10 µg/mL), moderate (10 < MIC ≤ 100 µg/mL), and low (MIC > 100 µg/mL) for natural compounds. In 2017, Tamokou et al. [61] further suggested the following cut-off points for edible parts of the plants: as highly active (MIC below 100 µg/mL), significant (100 ≤ MIC ≤ 512 µg/mL), moderate (512 < MIC ≤ 2048 µg/mL), low (MIC > 2048 µg/mL) and not active (MIC > 10 mg/mL) for botanicals but also the following for phytochemicals: highly active (MIC below 1 µg/mL or 2.5 µM), significantly active (1 ≤ MIC ≤ 10 µg/mL or 2.5 ≤ MIC < 25 µM), moderately active (10 < MIC ≤ 100 µg/mL or 25 ≤ MIC < 250 µM), low activity (100 < MIC ≤ 1000 µg/mL or 250 ≤ MIC < 2500 µM), and not active (MIC > 1000 µg/mL or > 2500 µM).

In 2023, Kuete and his team provided a rational basis for the classification of the antibacterial activity of plant-based products, taking into account the percentage of active extract in a selected bacterial type; from such basis, the following values were proposed.

In Enterobacteriaceae: outstanding when MIC ≤ 8 µg/mL; excellent when 8 < MIC ≤ 64 µg/mL; very good when 64 < MIC ≤ 128 µg/mL; good when 128 < MIC ≤ 256 µg/mL, average when 256 < MIC ≤ 512 µg/mL, weak when 512 < MIC ≤ 1024 µg/mL, and not active MIC > 1024 µg/mL for botanicals, outstanding when MIC ≤ 2 µg/mL, excellent when 2 < MIC ≤ 4 µg/mL, very good when 4 < MIC ≤ 8 µg/mL, good when 8 < MIC ≤ 32 µg/mL, average when 32 < MIC ≤ 64 µg/mL, weak when 64 < MIC ≤ 512 µg/mL, and not active when MIC > 512 µg/mL for plant constituents [52];

In Pseudomonas aeruginosa: outstanding when MIC ≤ 32 µg/mL, excellent when 32 < MIC ≤ 128 µg/mL, very good when 128 < MIC ≤ 256 µg/mL, good when 256 < MIC ≤ 512 µg/mL, average when 512 < MIC ≤ 1024 µg/mL, weak or not active when MIC values > 1024 µg/mL for crude extracts, outstanding when MIC ≤ 4 µg/mL, excellent when 4 < MIC ≤ 32 µg/mL, very good when 32 < MIC ≤ 128 µg/mL, good when 128 < MIC ≤ 256 µg/mL, average when 256 < MIC ≤ 512 µg/mL, weak or not active when MIC values > 512 µg/mL for phytochemicals [53];

In Gram-positive bacteria: outstanding when MIC ≤ 8 µg/mL, excellent when 8 < MIC ≤ 40 µg/mL, very good when 40 < MIC ≤ 128 µg/mL, good when 128 < MIC ≤ 320 µg/mL, average when 320 < MIC ≤ 625 µg/mL, weak when 625 < MIC ≤ 1024

µg/mL and not active when MIC values > 1024 µg/mL for crude extracts, outstanding when MIC ≤ 2 µg/mL, excellent when 2 < MIC ≤ 4 µg/mL, very good when 4 < MIC ≤ 8 µg/mL, good when 8 < MIC ≤ 32 µg/mL, average when 32 < MIC ≤ 64 µg/mL, weak when 64 < MIC ≤ 512 µg/mL, and not active when MIC > 512 µg/mL for phytochemicals [54];

In mycobacteria: outstanding when MIC ≤ 6 µg/mL, excellent when 6 < MIC ≤ 16 µg/mL, very good when 16 < MIC ≤ 25 µg/mL, good when 25 < MIC ≤ 39 µg/mL, average when 39 < MIC ≤ 156 µg/mL, weak when 156 < MIC ≤ 2048 µg/mL, and not active MIC > 2048 µg/mL for crude extracts, outstanding when MIC ≤ 2.5 µg/mL, excellent when 2.5 < MIC ≤ 5 µg/mL, very good when 5 < MIC ≤ 8 µg/mL, good when 8 < MIC ≤ 10 µg/mL, average when 10 < MIC ≤ 20 µg/mL, weak when 20 < MIC ≤ 512 µg/mL, and not active when MIC > 512 µg/mL for phytochemicals [55].

The best botanicals and phytochemicals

In the present review, the latest cut-off points proposed by Kuete and his team will be used to report the botanicals and phytochemicals with outstanding antibacterial effects identified in the flora of Africa against various bacterial species.

Against Enterobacteria

Number of African plant extracts were investigated against Enterobacteria, mainly *Escherichia coli*, *Enterobacter aerogenes*, *Enterobacter cloacae*, *Klebsiella pneumoniae*, and *Providencia stuartii*. Many of them displayed outstanding (MIC ≤ 8 µg/mL) against at least one bacterium belonging to Enterobacteriaceae family. The crude methanol extract from the roots of *Macaranga capensis* Benth. (Euphorbiaceae) displayed MIC values of 4 µg/mL against *E. coli* ATCC8739 and the MDR AG102 and *Enterobacter aerogenes* EA27 strains, 8 µg/mL against *Klebsiella pneumoniae* ATCC11296 and the MDR KP55 and *Providencia stuartii* NAE16 strains [62]; The MIC values of 8 µg/mL or lower were recorded with the bark methanol extract of *Harungana madagascariensis* Lam. ex Poir. (Hypericaceae) against *E. coli* ATCC8739, ATCC10536, and W3110 [63] as well as the stem extract of *Macaranga conglomerata* Brenan (Euphorbiaceae) against *E. coli* ATCC8739, AG102, EA27 strains, KP55 strains [62]. The methanol extract from the roots of *Macaranga kilimandscharica* Pax. Showed MIC value of 8 µg/mL against *Enterobacter aerogenes* ATCC13048, *K. pneumoniae* ATCC11296, *K. pneumoniae* KP55, and *P. stuartii* ATCC29914 strains [62]. The bark methanol extract of *Beilschmiedia acuta* Kosterm. (Lauraceae) had a MIC value below 8 µg/mL against *K. pneumoniae* ATCC11296 [64]. The methanol extract of the leaves of *Acacia polyacantha* Willd. (Fabaceae) and *Uapaca togoensis* Pax. (Euphorbiaceae) displayed a MIC value of 8 µg/mL against *P. stuartii* ATCC29914 [65] and PS2636 [66] strains, respectively

Several phytochemicals identified in African plants also displayed outstanding (MIC ≤ 2 µg/mL) antibacterial activities against Enterobacteria. For instance, the phenylpropanoid 8,8-bis-(dihydroconiferyl) diferulate (4) isolated from *Hypericum roeperianum* had MIC value of 0.5 µg/mL against *E. coli* ATCC8739, *K. pneumoniae* KP55, and *P. stuartii* ATCC29914, 1 µg/mL against AG102, and *P. stuartii* NEA16 strains, 2 µg/mL against *E. aerogenes* ATCC13048, CM64, and *K. pneumoniae* ATCC11296 strains [67], meanwhile, two other xanthenes isolated from *H. roeperianum*, 1,3,5,7-tetrahydroxanthone (3) and 1,3,5,6-tetrahydroxanthone (2) also displayed a MIC value of 2 µg/mL against *E. coli* ATCC8739, *E. aerogenes* ATCC13048, and *K. pneumoniae* KP55 strains [67]. The naphthoquinone plumbagin

(16) isolated *Diospyros canaliculata*, *Diospyros crassiflora* had a MIC value of 2 µg/mL against AG100A [68-70]. The chemical structures are shown in Figure 1.

Against *Pseudomonas aeruginosa*

P. aeruginosa is frequently resistant to many commonly used antibiotics [71, 72]. This bacterium including its resistant phenotype was sensitive to various African plant extracts and their phytochemicals [14, 45, 47, 64, 73-76]. Many of the reported botanicals (MIC ≤ 32 µg/mL) displayed outstanding and phytochemicals (MIC ≤ 4 µg/mL) against *P. aeruginosa*. For instance, the dichloromethane-methanol 1:1 extract from roots of *M. kilimandscharica* [62] displayed MIC values of 16 µg/mL against *P. aeruginosa* PA01 and the MDR PA124 strain, meanwhile, the MIC of 32 µg/mL was recorded against PA01 with the methanol extract from the bark of *H. madagascariensis* Lam ex. Poir. (Hypericaceae) [63] and the bark of *Mangifera indica* Linn. (Anacardiaceae) [77], the fruits of *Piper nigrum* L. (Piperaceae) [47], the root extracts of *M. capensis* and the stem of *M. conglomerata* [62]. Against PA124, the methanol extract from *M. capensis* had a MIC of 16 µg/mL [62], meanwhile, that of the bark of *Beilschmiedia acuta* Kosterm. (Lauraceae) had a MIC of 32 µg/mL [64]. Akoue and his team demonstrated that the methanol extract from the leaves of *Piptadeniastrum africanum* (Hook. F.) Brenan (Fabaceae) and *Tristemma mauritianum* J.F. Gmel (Melastomataceae) displayed MIC a value of 3.13 µg/mL against *P. aeruginosa* PA383 strain, those from the fruits of *Alchornea floribunda* Müller Arg. (Euphorbiaceae) and *Eriosema glomeratum* (Guill. & Perr.) Hook. F. (Fabaceae) had MIC a value of 6.25 µg/mL meanwhile that from the fruits of *Medinilla mirabilis* (Gilg) Jacq.-Fél. (Melastomataceae) displayed a MIC of 12.5 µg/mL [78].

Several phytochemicals from African medicinal plants displayed outstanding antibacterial (MIC ≤ 4 µg/mL) effects, and consequently be considered as good candidates to develop phytodrugs. In effect, the flavonoid dorsmanin C (10) isolated from the Cameroonian medicinal plant *Dorstenia mannii* had a MIC of 4 µg/mL against PA01 strain [79]. Against *P. aeruginosa* CRPA LMP0102U strain, the flavonoid bartericin A (8) isolated from *Dorstenia angusticornis* had a MIC of below 0.31 µg/mL [11], the phenylpropanoid 2-(4-hydroxyphenyl)-ethyltriacontanoate (1) isolated from *Newbouldia laevis* had a MIC of 0.31 µg/mL [80], anthraquinones 2-hydroxy-3-methoxy-9,10-dioxo-9,10-dihydroanthracene-1-carbaldehyde (5) isolated from *N. laevis* [80] and the xanthone allanxanthone D (6) isolated from *Allanblackia gabonensis* [81] had a MIC value of 0.61 µg/mL, another anthraquinone, vismiaquinone (17), isolated from *Vismia laurentii* displayed a MIC value of 2.44 µg/mL [82]. Against *P. aeruginosa* ATCC27853, Teke et al. recorded a MIC value of 0.62 µg/mL for the flavonoid isoliquiritigenin (13) isolated from *Trilepisium madagascariense* [83]. The chemical structures are shown in Figure 1.

Against Gram-positive bacteria

Gram-positive bacteria are responsible for several serious hospital and community infections such as nosocomial infections, sepsis, pneumonia, and toxoinosis [84, 85]. This antibacterial control of Gram-positive pathogens is hampered by the development of MDR phenotypes [86]. Medicinal plants are an undeniable source of medicine to fight bacterial resistance of Gram-positive bacteria. During the three last decades, number of African medicinal plant extracts and their constituents were successfully screened against Gram-positive bacteria mostly *Staphylococcus aureus* [11, 26, 80,

82, 87-100]. Many of the tested botanicals and phytochemicals inhibited the growth of resistant strains of *S. aureus* [101-108]. Many of the reported botanicals (MIC \leq 8 $\mu\text{g/mL}$) displayed outstanding and phytochemicals (MIC \leq 2 $\mu\text{g/mL}$) against Gram-positive bacteria. For instance, extract from *M. capensis* displayed MIC values of 4 $\mu\text{g/mL}$ against *S. aureus* MRSA6 and MRSA3, and 8 $\mu\text{g/mL}$ against ATCC25923 and MRSA3 strains [62]. Hashim and his collaborators also reported MIC values of 4 $\mu\text{g/mL}$ against *S. aureus* ATCC25923, and 8 $\mu\text{g/mL}$ against MRSA3 and MRSA6 with the crude extract from *M. kilimandscharica* [62]. *M. conglomerata* crude extract also had MIC values of 8 $\mu\text{g/mL}$ against *S. aureus* ATCC25923 and MRSA6 [62]. The phytochemical **16** was identified as an excellent anti-staphylococcal compound with a MIC value of 2 $\mu\text{g/mL}$ against MRSA4 and MRSA 8 [104]. The flavonoid isobavachalcone (**12**) isolated from *Dorstenia barteri* also had MIC values of 0.3 $\mu\text{g/mL}$ against *Streptococcus faecalis*, *S. aureus*, *Bacillus stearothermophilus* and 0.6 $\mu\text{g/mL}$ against *Bacillus cereus*, *Bacillus megaterium* and *Bacillus subtilis* [109]. Kuete et al. the outstanding antibacterial effect effects of the flavonoids isolated from *Dorstenia angusticornis*, namely gancaonin Q (**11**) with a Mic value of 0.61 $\mu\text{g/mL}$ against *B. cereus* and *S. faecalis*, 0.61 $\mu\text{g/mL}$ with compound **8** against *B. cereus*, *S. aureus*, and *S. faecalis*, and 1.22 $\mu\text{g/mL}$ against *B. megaterium* and *B. subtilis*, and 1.22 $\mu\text{g/mL}$ with angusticornin B (**7**) against *B. cereus*, *B. subtilis*, and *S. faecalis* [11].

Against mycobacteria

Tuberculosis (TB) is an infectious, endemic disease with a predominant human-to-human transmission, caused by the *Mycobacterium tuberculosis* Complex (MTBC) « *M. tuberculosis*, *M. bovis*, *M. africanum*, *M. microti*, *M. canettii*, *M. caprae*, *M. pinnipedii*, and *M. mungi* » [110]. It represents one of the top 10 causes of death worldwide [111] and according to the World Health Organization (WHO), an average of 10 million people develop an active form of the disease each year [112]. TB remains a public health concern in many industrialized countries, particularly when it comes to multidrug-resistant forms due to non-adherence to anti-tuberculosis drugs, which have a long treatment duration (> 2 years) [113]. Drug-resistant strains of *M. tuberculosis* (Mtb) are of particular concern worldwide because resistance occurs soon after a new chemotherapeutic agent is introduced into the market just as with other bacterial diseases. Several secondary plant metabolites are reported to have anti-tuberculosis activity comparable to existing anti-tuberculosis drugs. Outstanding (MIC \leq 6 $\mu\text{g/mL}$) was recorded on *M. tuberculosis* H37Rv with the methanol extract from the leaves of *Artemisia abyssinica* Schultz Bip. (Lamiaceae) [114]. A, outstanding (MIC \leq 2.5 $\mu\text{g/mL}$) antibacterial activity was recorded with O¹-demethyl-3',4'-deoxy-psorospermi-3',4' diol (**15**) isolated from *Vismia guineensis* [115] and laburnetin (**14**) isolated from *Ficus chlamydocarpa* [89] against *Mycobacterium smegmatis* with a MIC value of 0.61 $\mu\text{g/mL}$. Against *M. smegmatis*, diospyrone (**9**) isolated from *Diospyros canaliculata* (MIC of 1.22 $\mu\text{g/mL}$) [68] and isobachalcone (MIC of 2.44 $\mu\text{g/mL}$) [116] also had outstanding antimycobacterial effects. Against *M. tuberculosis* H37Rv strain, a MIC value of 2.44 $\mu\text{g/mL}$ was obtained with compounds **9** and **12** [68, 116].




Figure 1. Chemical structures of the best antibacterial phytochemicals from the flora of Africa.

1: 2-(4-hydroxyphenyl)-ethyltriacontanoate; 2: 1,3,5,6-tetrahydroxanthone; 3: 1,3,5,7-tetrahydroxanthone; 4: 8,8-bis-(dihydroconiferyl) diferulate; 5: 2-hydroxy-3-methoxy-9,10-dioxo-9,10-dihydroanthracene-1-carbaldehyde; 6: allanxanthone D; 7: *angusticornin* B; 8: bartericin A; 9: diospyrone; 10: dorsmanin C; 11: gancaonin Q; 12: isobavachalcone; 13: isoliquiritigenin; 14: laburnetin; 15: O¹-demethyl-3',4'-deoxy-psorospermi-3',4' diol; 16: plumbagin; 17: vismiaquinone.

Table 1. History of the publications related to bacteria and plant in African countries where most investigations were performed as recorded in PubMed.

Country	Number of papers*	First paper	Publication year	Reference
Egypt	1115	The antibacterial properties of the <i>Nigella sativa</i> L. seeds. Active principle with some clinical applications	1965	[56]
South Africa	771	Assessment of exposure to chloramphenicol and azathioprine among workers in a South African pharmaceutical plant	1993	[117]
Nigeria	399	The antibacterial properties of the buffer extracts of chewing sticks used in Nigeria	1975	[118]
Tunisia	362	Nauplathizine, a new unusual O-heteroside from <i>Nauplius aquaticus</i> (L)	2005	[119]
Cameroon	337	Sigmoidins J and K, two new prenylated isoflavonoids from <i>Erythrina sigmoidea</i>	1994	[120]
Morocco	271	Disseminating infection with <i>Scytalidium dimidiatum</i> in a granulocytopenic child	1993	[121]
Ethiopia	200	A novel antibacterial diterpene from <i>Premna schimperi</i>	1990	[122]
Algeria	177	HM17, a new polyene antifungal antibiotic produced by a new strain of <i>Spirillospora</i>	1994	[123]
Kenya	94	Antibiotic action of <i>Solanum incanum</i> Linnaeus	1976	[124]
Ghana	83	Antimicrobial properties of some West African medicinal plants iv. Antimicrobial activity of xylopic acid and other constituents of the fruits of <i>Xylopiya aethiopica</i> (Annonaceae)	1977	[125]
Sudan	66	Investigation of <i>Grewia bicolor</i> Juss.	1986	[126]

*The number of plants recorded in PubMed using keywords “country + plant + antibacterial” up to April 2024.

Conclusion

In the present review, we have compiled the best botanicals and phytochemicals from the flora of Africa that deserve clinical studies to develop novel antibacterial medication to combat drug sensitive and MDR phenotypes. The infections targeted were related to enterobacteria, *Pseudomonas aeruginosa*, Gram-positive bacteria, and mycobacteria. The entities include the botanicals from *Acacia polyacantha*, *Beilschmiedia acuta*, *Harungana madagascariensis*, *Macaranga capensis*, *Macaranga conglomerata*, *Macaranga kilimandscharica*, *Uapaca togoensis* and phytochemicals such as 8,8-bis-(dihydroconiferyl) diferulate (4), 1,3,5,7-tetrahydroxyxanthone (3), 1,3,5,6-tetrahydroxyxanthone (2), and plumbagin (16) for infections caused by enterobacteria, the crude extracts from *Alchornea floribunda*, *B. acuta*, *Eriosema glomeratum*, *H. madagascariensis*, *M. conglomerata*, *M. kilimandscharica* and plant constituents such as compounds 8, 16, *angusticornin* B (7), gancaonin Q (11), and isobavachalcone (12), for infections caused Gram-positive bacteria, the crude extract from *Artemisia abyssinica* as well as compounds such as compound 12, diospyrone (9), laburnetin (14), and O¹-demethyl-3',4'-deoxy-psorospermi-3',4' diol (15) for infections caused mycobacteria. The identified botanicals and phytochemicals deserve clinical investigations to develop novel antibacterial agents to combat bacterial infections.

Abbreviations

ATCC: American-Type Culture Collection
 MDR: multidrug-resistant
 MIC: minimal inhibitory concentration

Authors' Contribution

VK collected the data, draft the manuscript, read, and approved the final version.

Conflict of interest

The authors declare no conflict of interest.

Article history:

Received: 24 March 2024
 Received in revised form: 02 May 2024
 Accepted: 02 May 2024
 Available online: 02 May 2024

References

- Doron S, Gorbach SL. 2008. Bacterial infections: overview. *International Encyclopedia of Public Health*.273–282.
- Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, Harbarth S, Hindler JF, Kahlmeter G, Olsson-Liljequist B *et al.* 2012. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. *Clin Microbiol Infect.* 18(3):268-281.
- Zhen X, Stålsby Lundborg C, Sun X, Zhu N, Gu S, Dong H. 2021. Economic burden of antibiotic resistance in China: a national level estimate for inpatients. *Antimicrob Resist Infect Control.* 10(1):5.
- Seukep AJ, Fokoua-Maxime CD, Mbuntcha HG, Chen G, Assob JCN, Tenniswood M, Sarker SD, Kuete V, Ming-Quan G. 2022. Bacterial Drug Efflux Pump Inhibitors from Plants. In: *Antimicrobial Resistance: Underlying Mechanisms and Therapeutic Approaches*. edn. Edited by Kumar V, Shriram V, Paul A, Thakur M. Singapore: Springer Singapore: 487-532.
- Fongang H, Mbaveng AT, Kuete V. 2023. Chapter One - Global burden of bacterial infections and drug resistance. *Advances in Botanical Research.* 106: 1-20. <https://doi.org/10.1016/bs.abr.2022.08.001>.
- Dadgostar P. 2019. Antimicrobial Resistance: Implications and Costs. *Infect Drug Resist.* 12:3903-3910.
- Cowan MM. 1999. Plant products as antimicrobial agents. *Clin Microbiol Rev.* 12(4):564-582.
- Harbone J. 1973. *Phytochemical methods: a guide to modern techniques of plant analysis.* London: Chapman & Hall.

9. Kuete V, Efferth T. 2011. Pharmacogenomics of Cameroonian traditional herbal medicine for cancer therapy. *J Ethnopharmacol.* 137(1):752-766.
10. Kuete V. 2014. 21 - Health Effects of Alkaloids from African Medicinal Plants. In: *Toxicological Survey of African Medicinal Plants*. edn. Edited by Kuete V: Elsevier: 611-633.
11. Kuete V, Simo IK, Ngameni B, Bigoga JD, Watchueng J, Kapguep RN, Etoa FX, Tchaleu BN, Beng VP. 2007. Antimicrobial activity of the methanolic extract, fractions and four flavonoids from the twigs of *Dorstenia angusticornis* Engl. (Moraceae). *J Ethnopharmacol.* 112(2):271-277.
12. Kuete V, Tangmouo JG, Penlap Beng V, Ngounou FN, Lontsi D. 2006. Antimicrobial activity of the methanolic extract from the stem bark of *Tridesmostemon omphalocarpoides* (Sapotaceae). *J Ethnopharmacol.* 104(1-2):5-11.
13. Kuete V, Dzotam JK, Voukeng IK, Fankam AG, Efferth T. 2016. Cytotoxicity of methanol extracts of *Annona muricata*, *Passiflora edulis* and nine other Cameroonian medicinal plants towards multi-factorial drug-resistant cancer cell lines. *Springerplus.* 5(1):1666.
14. Fankam AG, Kuete JR, Kuete V. 2015. Antibacterial and antibiotic resistance modifying activity of the extracts from *allanblackia gabonensis*, *combretum molle* and *gladiolus quartianianus* against Gram-negative bacteria including multi-drug resistant phenotypes. *BMC Complement Altern Med.* 15:206.
15. Tekwu EM, Askun T, Kuete V, Nkengfack AE, Nyasse B, Etoa FX, Beng VP. 2012. Antibacterial activity of selected Cameroonian dietary spices ethno-medically used against strains of *Mycobacterium tuberculosis*. *J Ethnopharmacol.* 142(2):374-382.
16. Kuete V. 2013. Medicinal Plant Research in Africa: Pharmacology and Chemistry In: *Pharmacology and Chemistry*. Edited by Kuete V, 1 edn. Oxford: Elsevier.
17. Kuete V, Mbaveng AT, Sandjo LP, Zeino M, Efferth T. 2017. Cytotoxicity and mode of action of a naturally occurring naphthoquinone, 2-acetyl-7-methoxynaphtho[2,3-b]furan-4,9-quinone towards multi-factorial drug-resistant cancer cells. *Phytomedicine.* 33:62-68.
18. Mbaveng AT, Kuete V, Mapunya BM, Beng VP, Nkengfack AE, Meyer JJ, Lall N. 2011. Evaluation of four Cameroonian medicinal plants for anticancer, antiongonrheal and antireverse transcriptase activities. *Environ Toxicol Pharmacol.* 32(2):162-167.
19. Nielsen TR, Kuete V, Jager AK, Meyer JJ, Lall N. 2012. Antimicrobial activity of selected South African medicinal plants. *BMC Complement Altern Med.* 12:74.
20. Kuete V, Wiench B, Alsaid MS, Alyahya MA, Fankam AG, Shahat AA, Efferth T. 2013. Cytotoxicity, mode of action and antibacterial activities of selected Saudi Arabian medicinal plants. *BMC Complement Altern Med.* 13:354.
21. Omosa LK, Midiwo JO, Kuete V. 2017. Chapter 19 - Curcuma longa. In: *Medicinal Spices and Vegetables from Africa*. edn. Edited by Kuete V: Academic Press: 425-435.
22. Kuete V, Sandjo LP, Mbaveng AT, Seukep JA, Ngadjui BT, Efferth T. 2015. Cytotoxicity of selected Cameroonian medicinal plants and *Nauclaea pobeguinii* towards multi-factorial drug-resistant cancer cells. *BMC Complement Altern Med.* 15:309.
23. Kuete V, Wansi JD, Mbaveng AT, Kana SOP MM, Tadjong AT, Beng VP, Etoa FX, Wandji J, Meyer JJM, Lall N. 2008. Antimicrobial activity of the methanolic extract and compounds from *Teclaea afzelii* (Rutaceae). *S Afr J Bot.* 74(4):572-576.
24. Kuete V, Mbaveng AT, Zeino M, Fozing CD, Ngameni B, Kapche GD, Ngadjui BT, Efferth T. 2015. Cytotoxicity of three naturally occurring flavonoid derived compounds (artocarpin, cycloartocarpin and isobavachalcone) towards multi-factorial drug-resistant cancer cells. *Phytomedicine.* 22(12):1096-1102.
25. Sandjo LP, Kuete V, Tohangna RS, Efferth T, Ngadjui BT. 2014. Cytotoxic benzophenanthridine and furoquinoline alkaloids from *Zanthoxylum buesgenii* (Rutaceae). *Chem Cent J.* 8(1):61.
26. Ngounou FN, Manfouo RN, Taponjou LA, Lontsi D, Kuete V, Penlap V, Etoa FX, Dubois MAL, Sondengam BL. 2005. Antimicrobial diterpenoid alkaloids from *Erythrophleum suaveolens* (guill. & perr.) brenan. *Bull Chem Soc Ethiop.* 19(2):221-226.
27. Dzoyem JP, Tchuenguem RT, Kuiate JR, Teke GN, Kechia FA, Kuete V. 2014. *In vitro* and *in vivo* antifungal activities of selected Cameroonian dietary spices. *BMC Complement Altern Med.* 14:58.
28. Mbaveng AT, Hamm R, Kuete V. 2014. 19 - Harmful and protective effects of terpenoids from african medicinal plants. In: *Toxicological Survey of African Medicinal Plants*. edn. Edited by Kuete V: Elsevier: 557-576.
29. Kuete V, Tabopda TK, Ngameni B, Nana F, Tshikalange TE, Ngadjui BT. 2010. Antimycobacterial, antibacterial and antifungal activities of *Terminalia superba* (Combretaceae). *S Afr J Bot.* 76(1):125-131.
30. Kuete V, Sandjo L, Seukep J, Maen Z, Ngadjui B, Efferth T. 2015. Cytotoxic compounds from the fruits of *Uapaca togoensis* towards multi-factorial drug-resistant cancer cells. *Planta Med.* 81(1):32-38.
31. Mbaveng AT, Chi GF, Bonsou IN, Ombito JO, Yeboah SO, Kuete V, Efferth T. 2020. Cytotoxic phytochemicals from the crude extract of *Tetrapleura tetraptera* fruits towards multi-factorial drug resistant cancer cells. *J Ethnopharmacol.* 267:113632.
32. Nyaboke HO, Moraa M, Omosa LK, Mbaveng AT, Vaderament-Alexe N-N, Masila V, Okemwa E, Heydenreich M, Efferth T, Kuete V. 2018. Cytotoxicity of lupel from the stem bark of *Zanthoxylum gillettii* against multi-factorial drug resistant cancer cell lines. *Invest Med Chem Pharmacol.* 1(1):10.
33. Mbaveng AT, Damen F, Celik I, Tane P, Kuete V, Efferth T. 2019. Cytotoxicity of the crude extract and constituents of the bark of *Fagara tessmannii* towards multi-factorial drug resistant cancer cells. *J Ethnopharmacol.* 235:28-37.
34. Bonsou IN, Mbaveng AT, Nguenang GS, Chi GF, Kuete V, Efferth T. 2022. Cytotoxicity, acute and sub-chronic toxicities of the fruit extract of *Tetrapleura tetraptera* (Schumm. & Thonn.) Taub. (Fabaceae). *BMC Complement Med Ther.* 22(1):178.
35. Mbaveng AT, Omosa LK, Bitchagno GTM, Kuete JRN, Nchiozem-Ngnitedem V-A, Kuete V. 2023. Chapter Eleven - Potential antibacterial pharmaceuticals from the flora of Africa. *Advances in Botanical Research.* 107: 307-352. <https://doi.org/10.1016/bs.abr.2022.08.021>.
36. Kuete V, Ngameni B, Wiench B, Krusche B, Horwedel C, Ngadjui BT, Efferth T. 2011. Cytotoxicity and mode of action of four naturally occurring flavonoids from the genus *Dorstenia*: gancaonin Q, 4-hydroxylochoncarpin, 6-prenylapigenin, and 6,8-diprenylorioidictol. *Planta Med.* 77(18):1984-1989.
37. Kuete V, Nkuete AHL, Mbaveng AT, Wiench B, Wabo HK, Tane P, Efferth T. 2014. Cytotoxicity and modes of action of 4'-hydroxy-2',6'-dimethoxychalcone and other flavonoids toward drug-sensitive and multidrug-resistant cancer cell lines. *Phytomedicine.* 21(12):1651-1657.
38. Kuete V, Efferth T. 2015. African flora has the potential to fight multidrug resistance of cancer. *BioMed Res Int.* 2015:914813.
39. Kuete V, Fankam AG, Wiench B, Efferth T. 2013. Cytotoxicity and modes of action of the methanol extracts of six Cameroonian medicinal plants against multidrug-resistant tumor cells. *Evid Based Complement Alternat Med.* 2013:285903.
40. Kuete V, Efferth T. 2010. Cameroonian medicinal plants: pharmacology and derived natural products. *Frontiers Pharmacol.* 1:123.
41. Mbaveng AT, Kuete V, Efferth T. 2017. Potential of Central, Eastern and Western Africa medicinal plants for cancer therapy: spotlight on resistant cells and molecular targets. *Front Pharmacol.* 8:343.
42. Efferth T, Kadioglu O, Saeed MEM, Seo EJ, Mbaveng AT, Kuete V. 2021. Medicinal plants and phytochemicals against multidrug-resistant tumor cells expressing ABCB1, ABCG2, or ABCB5: a synopsis of 2 decades. *Phytochem Rev.* 20(1):7-53.
43. Efferth T, Saeed MEM, Kadioglu O, Seo EJ, Shirooie S, Mbaveng AT, Nabavi SM, Kuete V. 2020. Collateral sensitivity of natural products in drug-resistant cancer cells. *Biotechnol Adv.* 38:107342.
44. Seukep JA, Ngadjui B, Kuete V. 2015. Antibacterial activities of *Fagara macrophylla*, *Canarium schweinfurthii*, *Myrianthus arboreus*, *Dischistocalyx grandifolius* and *Tragia benthamii* against multi-drug resistant Gram-negative bacteria. *Springerplus.* 4:567.
45. Tankeo SB, Lacmata ST, Noumedem JA, Dzoyem JP, Kuiate JR, Kuete V. 2014. Antibacterial and antibiotic-potential activities of some Cameroonian food plants against multi-drug resistant Gram-negative bacteria. *Chin J Integr Med.* 20(7):546-554.
46. Kuete V. 2023. Chapter Twelve - Ethnopharmacology, phytochemistry and pharmacology of potent antibacterial medicinal plants from Africa. *Advances in Botanical Research.* 107:353-660. <https://doi.org/10.1016/bs.abr.2022.08.022>.
47. Noumedem JA, Mihasan M, Kuiate JR, Stefan M, Cojocararu D, Dzoyem JP, Kuete V. 2013. *In vitro* antibacterial and antibiotic-potential activities of four edible plants against multidrug-resistant Gram-negative species. *BMC Complement Altern Med.* 13:190.
48. Dzotam JK, Touani FK, Kuete V. 2016. Antibacterial activities of the methanol extracts of *Canarium schweinfurthii* and four other Cameroonian dietary plants against multi-drug resistant Gram-negative bacteria. *Saudi J Biol Sci.* 23:565-570.
49. Dzotam JK, Kuete V. 2017. Antibacterial and antibiotic-modifying activity of methanol extracts from six cameroonian food plants against multidrug-resistant enteric bacteria. *BioMed Res Int.* 2017:1583510.
50. Dzotam JK, Simo IK, Bitchagno G, Celik I, Sandjo LP, Tane P, Kuete V. 2018. *In vitro* antibacterial and antibiotic modifying activity of crude extract, fractions and 3',4',7'-trihydroxyflavone from *Myristica fragrans* Houtt against MDR Gram-negative enteric bacteria. *BMC Complement Altern Med.* 18(1):15.
51. Seukep JA, Sandjo LP, Ngadjui BT, Kuete V. 2016. Antibacterial and antibiotic-resistance modifying activity of the extracts and compounds from *Nauclaea pobeguinii* against Gram-negative multi-drug resistant phenotypes. *BMC Complement Altern Med.* 16:193.
52. Kuete V. 2023. Chapter Six - Potential of African medicinal plants against Enterobacteria: Classification of plants antibacterial agents. *Advances in Botanical Research.* 106: 151-335. <https://doi.org/10.1016/bs.abr.2022.08.006>.
53. Tankeo SB, Kuete V. 2023. Chapter Seven - African plants acting on Pseudomonas aeruginosa: Cut-off points for the antipseudomonal agents from plants. *Advances in Botanical Research.* 106: 337-412. <https://doi.org/10.1016/bs.abr.2022.08.007>.
54. Wamba BEN, Mbaveng AT, Kuete V. 2023. Chapter Eight - Fighting Gram-positive bacteria with African medicinal plants: Cut-off values for the classification of the activity of natural products. *Advances in Botanical Research.* 106: 2023: 413-522. <https://doi.org/10.1016/bs.abr.2022.08.008>.
55. Tchinda CF, Kuete V. 2023. Chapter Nine - Potential of African flora to combat tuberculosis and drug resistance of Mycobacteria: Rationale classification of antimycobacterial agents from a natural source. *Advances in Botanical Research.* 106: 523-598. <https://doi.org/10.1016/bs.abr.2022.08.009>.
56. Topozada HH, Mazloum HA, el-Dakhakhny M. 1965. The antibacterial properties of the *Nigella sativa* L. seeds. Active principle with some clinical applications. *J Egypt Med Assoc.* 48:Suppl:187-202.
57. Fabry W, Okemo P, Ansorg R. 1998. Antibacterial activity of East African medicinal plants. *J Ethnopharmacol.* 60:79-84.
58. Simões M, Bennett R, Rosa E. 2009. Understanding antimicrobial activities of phytochemicals against multidrug resistant bacteria and biofilms. *Nat Prod Rep.* 26:746-757.
59. Jimenez-Arellanes A, Meckes M, Ramirez R, Torres J, Luna-Herrera J. 2003. Activity against multidrug-resistant *Mycobacterium tuberculosis* in Mexican plants used to treat respiratory diseases. *Phytother Res.* 17(8):903-908.
60. Kuete V. 2010. Potential of Cameroonian plants and derived products against microbial infections: a review. *Planta Med.* 76(14):1479-1491.
61. Tamokou JDD, Mbaveng AT, Kuete V. 2017. Chapter 8 - Antimicrobial Activities of African Medicinal Spices and Vegetables. In: *Medicinal Spices and Vegetables from Africa*. edn.: Academic Press: 207-237.
62. Hashim I, Omosa LK, Nchiozem-Ngnitedem VA, Onyari JM, Maru SM, Guefack MGF, Mbaveng AT, Kuete V. 2021. Antibacterial activities and phytochemical screening of crude extracts from Kenyan *Macaranga* species towards MDR phenotypes expressing efflux pumps. *Pharmacogn Commun.* 11(2):119-126.
63. Tankeo SB, Damen F, Sandjo LP, Celik I, Tane P, Kuete V. 2016. Antibacterial activities of the methanol extracts, fractions and compounds from *Harungana madagascariensis* Lam. ex Poir. (Hypericaceae). *J Ethnopharmacol.* 190:100-105.
64. Tankeo SB, Tane P, Kuete V. 2015. *In vitro* antibacterial and antibiotic-potential activities of the methanol extracts from *Beilschmiedia acuta*, *Clausena anisata*, *Newbouldia laevis* and *Polyscias fulva* against multidrug-resistant Gram-negative bacteria. *BMC Complement Altern Med.* 15(1):412.
65. Mambe FT, Na-lya J, Fotoso GW, Ashu F, Ngameni B, Ngadjui BT, Beng VP, Kuete V. 2019. Antibacterial and antibiotic modifying potential of crude extracts, fractions, and compounds from *Acacia polyacantha* Willd. against MDR Gram-negative bacteria. *Evid Based Complement Alternat Med.* 2019:7507549.
66. Seukep JA, Sandjo LP, Ngadjui BT, Kuete V. 2016. Antibacterial activities of the methanol extracts and compounds from *Uapaca togoensis* against Gram-negative multi-drug resistant phenotypes. *S Afr J Bot.* 103:1-5.
67. Demgne OMF, Damen F, Fankam AG, Guefack MF, Wamba BEN, Nayim P, Mbaveng AT, Bitchagno GTM, Taponjou LA, Penlap VB, Tane P, Efferth T, Kuete V. 2021. Botanicals and phytochemicals from the bark of *Hypericum roeperianum* (Hypericaceae) had strong antibacterial activity and showed synergistic effects with

- antibiotics against multidrug-resistant bacteria expressing active efflux pumps. *J Ethnopharmacol*. 277:114257.
68. Kuete V, Tangmouo JG, Marion Meyer JJ, Lall N. 2009. Diospyrone, crassiflorone and plumbagin: three antimycobacterial and antigonorrhoeal naphthoquinones from two *Diospyros* spp. *Int J Antimicrob Ag*. 34(4):322-325.
 69. Kuete V, Omosa LK, Tala VR, Midwo JO, Mbaveng AT, Swaleh S, Karaosmanoglu O, Sivas H. 2016. Cytotoxicity of plumbagin, rapanone and 12 other naturally occurring quinones from Kenyan flora towards human carcinoma cells. *BMC Pharmacol Toxicol*. 17(1):60.
 70. Kuete V, Alibert-Franco S, Eyong KO, Ngameni B, Folefoc GN, Nguemeving JR, Tangmouo JG, Fotso GW, Komgum J, Ouahouo BMW *et al*. 2011. Antibacterial activity of some natural products against bacteria expressing a multidrug-resistant phenotype. *Int J Antimicrob Ag*. 37(2):156-161.
 71. Gale EF. 1981. Molecular basis of antibiotic action, vol. 2nd edn. Chichester, Brisbane, New York and Toronto: J. Wiley.
 72. Aleksun MN, Levy SB. 2007. Molecular mechanisms of antibacterial multidrug resistance. *Cell*. 128(6):1037-1050.
 73. Fankam AG, Kuete JR, Kuete V. 2017. Antibacterial and antibiotic resistance modulatory activities of leaves and bark extracts of *Recinodindron heudelotii* (Euphorbiaceae) against multidrug-resistant Gram-negative bacteria. *BMC Complement Altern Med*. 17(1):168.
 74. Tchinda CF, Voukeng KI, Beng VP, Kuete V. 2016. Antibacterial activities of the methanol extracts of *Albizia adianthifolia*, *Alchornea laxiflora*, *Laportea ovalifolia* and three other Cameroonian plants against multi-drug resistant Gram-negative bacteria *Saudi J Biol Sci*. 24:950-955.
 75. Fankam AG, Kuete JR, Kuete V. 2014. Antibacterial activities of *Beilschmiedia obscura* and six other Cameroonian medicinal plants against multi-drug resistant Gram-negative phenotypes. *BMC Complement Altern Med*. 14:241.
 76. Voukeng IK, Kuete V, Dzoyem JP, Fankam AG, Noumedem JA, Kuete JR, Pages JM. 2012. Antibacterial and antibiotic-potentiating activities of the methanol extract of some Cameroonian spices against Gram-negative multi-drug resistant phenotypes. *BMC Res Notes*. 5:299.
 77. Dzotam J, Kuete V. 2017. Antibacterial activity of methanol extracts from six Cameroonian edible plants *Camellia sinensis*, *Mangifera indica*, *Moringa oleifera*, *Ananas comosus*, *Triumfetta pentandra* and *Artocarpus heterophyllus* against MDR Gram-Negative phenotypes. *African Journal of Integrated Health*. 7(2):49-56.
 78. Akoue GN, Nguema PPM, Onanga R, Mabika AM, Ibrahim B. 2019. Nutritional prospects, antioxidant and antibacterial activities of some food plants consumed by wild mandrill (*Mandrillus sphinx*) population from Iékédi park (Bakoumba, Gabon). *Int J Adv Res*. 7(2):116-136.
 79. Mbaveng AT, Kuete V, Ngameni B, Beng VP, Ngadjui BT, Meyer JJ, Lall N. 2012. Antimicrobial activities of the methanol extract and compounds from the twigs of *Dorstenia mannii* (Moraceae). *BMC Complement Altern Med*. 12:83.
 80. Kuete V, Eyong KO, Folefoc GN, Beng VP, Hussain H, Krohn K, Nkengfack AE. 2007. Antimicrobial activity of the methanolic extract and of the chemical constituents isolated from *Newbouldia laevis*. *Pharmazie*. 62(7):552-556.
 81. Azebaze AG, Ouahouo BM, Vardamides JC, Valentin A, Kuete V, Acebey L, Beng VP, Nkengfack AE, Meyer M. 2008. Antimicrobial and antileishmanial xanthenes from the stem bark of *Allanblackia gabonensis* (Guttiferae). *Nat Prod Res*. 22(4):333-341.
 82. Kuete V, Nguemeving JR, Beng VP, Azebaze AG, Etoa FX, Meyer M, Bodo B, Nkengfack AE. 2007. Antimicrobial activity of the methanolic extracts and compounds from *Vismia laurentii* De Wild (Guttiferae). *J Ethnopharmacol*. 109(3):372-379.
 83. Teke GN, Kuete JR, Kueté V, Teponno RB, Taponjoui LA, Tane P, Giacinti G, Viliarem G. 2011. Bio-guided isolation of potential antimicrobial and antioxidant agents from the stem bark of *Tripelision madagascariense*. *S Afr J Bot*. 77(2):319-327.
 84. Johnson AP. 2011. Methicillin-resistant *Staphylococcus aureus*: the European landscape. *J Antimicrob Chemother*. 66 Suppl 4:iv43-iv48.
 85. Taj Y, Essa F, Aziz F, Kazmi SU. 2012. Study on biofilm-forming properties of clinical isolates of *Staphylococcus aureus*. *J Infect Dev Ctries*. 6(5):403-409.
 86. Rice LB. 2006. Unmet medical needs in antibacterial therapy. *Biochem Pharmacol*. 71(7):991-995.
 87. Komgum J, Meli AL, Manfouo RN, Lonsi D, Ngounou FN, Kuete V, Kamdem HW, Tane P, Ngadjui BT, Sondengam BL *et al*. 2005. Xanthenes from *Garcinia smeathmannii* (Oliver) and their antimicrobial activity. *Phytochemistry*. 66(14):1713-1717.
 88. Kuete V, Tangmouo JG, Penlap Beng V, Ngounou FN, Lonsi D. 2006. Antimicrobial activity of the methanolic extract from the stem bark of *Tridesmostemon omphalocarpoides* (Sapotaceae). *J Ethnopharmacol*. 104(1-2):5-11.
 89. Kuete V, Ngameni B, Simo CC, Tankeu RK, Ngadjui BT, Meyer JJ, Lall N, Kuete JR. 2008. Antimicrobial activity of the crude extracts and compounds from *Ficus chlamydocarpa* and *Ficus cordata* (Moraceae). *J Ethnopharmacol*. 120(1):17-24.
 90. Kuete V, Nana F, Ngameni B, Mbaveng AT, Keumedjio F, Ngadjui BT. 2009. Antibacterial activity of the crude extract, fractions and compounds from stem bark of *Ficus ovata* (Moraceae). *J Ethnopharmacol*. 124(3):556-561.
 91. Kuete V, Tabopda TK, Ngameni B, Nana F, Tshikalange TE, Ngadjui BT. 2010. Antimycobacterial, antibacterial and antifungal activities of *Terminalia superba* (Combretaceae). *S Afr J Bot*. 76(1):125-131.
 92. Nono EC, Mkounga P, Kuete V, Marat K, Hultin PG, Nkengfack AE. 2010. Pycnanthuligenes A-D, antimicrobial cyclolignene derivatives from the roots of *Pycnanthus angolensis*. *J Nat Prod*. 73(2):213-216.
 93. Ngameni B, Kuete V, Simo IK, Mbaveng AT, Awoussong PK, Patnam R, Roy R, Ngadjui BT. 2009. Antibacterial and antifungal activities of the crude extract and compounds from *Dorstenia turbinata* (Moraceae). *S Afr J Bot*. 75(2):256-261.
 94. Kuete V, Metuno R, Ngameni B, Tsafack AM, Ngandeu F, Fotso GW, Bezabih M, Etoa F-X, Ngadjui BT, Abegaz BM *et al*. 2007. Antimicrobial activity of the methanolic extracts and compounds from *Treulia obovoidea* (Moraceae). *J Ethnopharmacol*. 112(3):531-536.
 95. Eyong KO, Folefoc GN, Kuete V, Beng VP, Krohn K, Hussain H, Nkengfack AE, Saeftel M, Sarite SR, Hoerauf A. 2006. Newbouldiaquinone A: A naphthoquinone-anthraquinone ether coupled pigment, as a potential antimicrobial and antimalarial agent from *Newbouldia laevis*. *Phytochemistry*. 67(6):605-609.
 96. Kuete V, Kamga J, Sandjo LP, Ngameni B, Poumale HM, Ambassa P, Ngadjui BT. 2011. Antimicrobial activities of the methanol extract, fractions and compounds from *Ficus polita* Vahl. (Moraceae). *BMC Complement Altern Med*. 11:6.
 97. Kuete V, Fozing DC, Kapche WF, Mbaveng AT, Kuete JR, Ngadjui BT, Abegaz BM. 2009. Antimicrobial activity of the methanolic extract and compounds from *Morus mesozygia* stem bark. *J Ethnopharmacol*. 124(3):551-555.
 98. Kuete V, Sandjo LP. 2012. Isobavachalcone: an overview. *Chin J Integr Med*. 18(7):543-547.
 99. Kuete V, Mbaveng AT, Tsafack M, Beng VP, Etoa FX, Nkengfack AE, Meyer JJM, Lall N. 2008. Antitumor, antioxidant and antimicrobial activities of *Bersama engleriana* (Melianthaceae). *J Ethnopharmacol*. 115(3):494-501.
 100. Kuete V, Ango PY, Fotso GW, Kapche GD, Dzoyem JP, Wouking AG, Ngadjui BT, Abegaz BM. 2011. Antimicrobial activities of the methanol extract and compounds from *Artocarpus communis* (Moraceae). *BMC Complement Altern Med*. 11:42.
 101. Manekeng HT, Mbaveng AT, Nguenang GS, Seukep JA, Wamba BEN, Nayim P, Yinku NR, Fankam AG, Kuete V. 2018. Anti-staphylococcal and antibiotic-potentiating activities of seven Cameroonian edible plants against resistant phenotypes. *Invest Med Chem Pharmacol*. 1:7.
 102. Wamba BEN, Nayim P, Mbaveng AT, Voukeng IK, Dzotam JK, Ngalani OJT, Kuete V. 2018. *Syzygium jambos* displayed antibacterial and antibiotic-modulating activities against resistant phenotypes. *Evid Based Complement Alternat Med*. 2018:5124735.
 103. Wamba BEN, Mbaveng AT, Nayim P, Dzotam JK, Ngalani OJT, Kuete V. 2018. Antistaphylococcal and antibiotic resistance modulatory activities of thirteen cameroonian edible plants against resistant phenotypes. *Int J Microbiol*. 2018:1920198.
 104. Omosa LK, Midwo JO, Mbaveng AT, Tankeo SB, Seukep JA, Voukeng IK, Dzotam JK, Isemeki J, Derese S, Omolle RA *et al*. 2016. Antibacterial activity and structure-activity relationships of a panel of 48 compounds from kenyan plants against multidrug resistant phenotypes. *SpringerPlus*. 5:901.
 105. Ashu FA, Na-Iya J, Wamba BEN, Kamga J, Nayim P, Ngameni B, Beng VP, Ngadjui BT, Kuete V. 2020. Antistaphylococcal Activity of Extracts, Fractions, and Compounds of *Acacia polyacantha* Wild (Fabaceae). *Evid Based Complement Alternat Med*. 2020:2654247.
 106. Ekamue B, Mbaveng AT, Kuete V. 2023. Anti-staphylococcal and antibiotic-potentiating activities of botanicals from nine Cameroonian food plants towards multidrug-resistant phenotypes. *Invest Med Chem Pharmacol*. 6(1):75.
 107. Kuete V. 2023. Ethnopharmacology, phytochemistry and pharmacology of potent antibacterial medicinal plants from Africa. *Advances in Botanical Research* 107: 353-660. <https://doi.org/10.1016/bs.abr.2022.08.022>.
 108. Badawe G, Fankam AG, Mbaveng AT, Wamba BEN, Nayim P, Kuete V. 2019. *Cinnamomum zeylanicum*, *Dichrostachys glomerata* and three other plants had anti-staphylococcal and antibiotic modifying activity against drug-resistant phenotypes. *Invest Med Chem Pharmacol*. 2:25.
 109. Mbaveng AT, Ngameni B, Kuete V, Simo IK, Ambassa P, Roy R, Bezabih M, Etoa FX, Ngadjui BT, Abegaz BM *et al*. 2008. Antimicrobial activity of the crude extracts and five flavonoids from the twigs of *Dorstenia barteri* (Moraceae). *J Ethnopharmacol*. 116(3):483-489.
 110. van Ingen J, Rahim Z, Mulder A, Boeree MJ, Simeone R, Brosch R, van Soolingen D. 2012. Characterization of *Mycobacterium orygis* as *M. tuberculosis* complex subspecies. *Emerg Infect Dis*. 18(4):653-655.
 111. Anochie PI, Ndingkokhar B, Bueno J, Anyiam FE, Ossai-Chidi LN, Onyeneke EC, Onyeozirila AC. 2018. African medicinal plants that can control or cure tuberculosis. *Int J Pharm Sci Dev Res*. 4(1):001-008.
 112. WHO. 2019. Global tuberculosis report 2019. https://www.who.int/publications/global_report/en 2020.
 113. Seung KJ, Keshavjee S, Rich ML. 2015. Multidrug-Resistant Tuberculosis and Extensively Drug-Resistant Tuberculosis. *Cold Spring Harb Perspect Med*. 5(9):a017863-a017863.
 114. Gemechu A, Giday M, Worku A, Ameni G. 2013. *In vitro* anti-mycobacterial activity of selected medicinal plants against *Mycobacterium tuberculosis* and *Mycobacterium bovis* strains. *BMC Complement Altern Med*. 13:291.
 115. Mbaveng AT, Kuete V, Nguemeving JR, Beng VP, Nkengfack AE, Marion Meyer JJ, Lall N, Krohn K. 2008. Antimicrobial activity of the extracts and compounds from *Vismia guineensis* (Guttiferae). *Asian J Trad Med*. 3:211-223.
 116. Kuete V, Ngameni B, Mbaveng AT, Ngadjui B, Meyer JJ, Lall N. 2010. Evaluation of flavonoids from *Dorstenia barteri* for their antimycobacterial, antigonorrhoeal and anti-reverse transcriptase activities. *Acta Trop*. 116(1):100-104.
 117. Jeebhay M, Mbali S, Uebel R. 1993. Assessment of exposure to chloramphenicol and azathioprine among workers in a South African pharmaceutical plant. *Int Arch Occup Environ Health*. 65(1 Suppl):S119-122.
 118. Fadulu SO. 1975. The antibacterial properties of the buffer extracts of chewing sticks used in Nigeria. *Planta Med*. 27(2):122-126.
 119. Chaari A, Ben Jannet H, Salmona G, Mighri Z. 2005. Nauplathizine, a new unusual O-heteroside from *Nauplius aquaticus* (L). *Nat Prod Res*. 19(5):523-528.
 120. Nkengfack AE, Vouffo TW, Vardamides JC, Fomum ZT, Bergendoff O, Sterner O. 1994. Sigmoidins J and K, two new prenylated isoflavonoids from *Erythrina sigmoidea*. *J Nat Prod*. 57(8):1172-1177.
 121. Benne CA, Neeleman C, Bruin M, de Hoog GS, Fleer A. 1993. Disseminating infection with *Scytalidium dimidiatum* in a granulocytopenic child. *Eur J Clin Microbiol Infect Dis*. 12(2):118-121.
 122. Habtemariam S, Gray AI, Halbert GW, Waterman PG. 1990. A novel antibacterial diterpene from *Premna schimperii*. *Planta Med*. 56(2):187-189.
 123. Hacène H, Kebir K, Othmane DS, Lefebvre G. 1994. HM17, a new polyene antifungal antibiotic produced by a new strain of *Sporisorium*. *J Appl Bacteriol*. 77(5):484-489.
 124. Beamam-Mbaya V, Muhammed SI. 1976. Antibiotic action of *Solanum incanum* Linnaeus. *Antimicrob Agents Chemother*. 9(6):920-924.
 125. Boakye-Yiadom K, Fiagbe NI, Ayim JS. 1977. Antimicrobial properties of some West African medicinal plants iv. Antimicrobial activity of xylopic acid and other constituent of the fruits of *Xylopic aethiopicum* (Annonaceae). *Lloydia*. 40(6):543-545.
 126. Jaspers MW, Bashir AK, Zwaving JH, Malingré TM. 1986. Investigation of *Grewia bicolor* Juss. *J Ethnopharmacol*. 17(3):205-211.